Daniel Smeak, DVM, ACVS, Joins Inotiv as Vice President, Surgical Models
January 11 2021 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the
“Company”, “We”, “Our” or “Inotiv”), doing business as
Inotiv, a leading provider of nonclinical and analytical contract
research services, today announced that Daniel Smeak, DVM,
ACVS, has joined the Company as Vice President, Surgical Models,
effective December 30, 2020.
Dr. Smeak is based at the Company’s Fort Collins, CO, site, a
facility in which the Company has recently invested nearly $1
million in upgrades and improvements, including mechanical upgrades
to improve energy efficiency, and room modifications to increase
capacity.
“Dan is a skilled and experienced surgeon, with humble
confidence and a commitment to delivering exceptional client
experience that aligns with Inotiv’s core values,” said Dr. Don
Maul, Sr. Vice President, Surgical Models. “Dan adds
credibility and versatility to the surgical device services we
provide our sponsors. His talent is a valuable asset as our Company
continues to solidify our position as a premier CRO in the United
States and beyond.”
Before joining Inotiv, Dr. Smeak enjoyed a thirteen-year career
at the Colorado State University Veterinary Teaching Hospital as
Professor and Chief of Small Animal Surgery and Dental/Oral
Surgery. Previously, Dr. Smeak was at The Ohio State
University for 27 years, where he advanced through the academic
ranks from assistant professor to professor, and then Section Head,
Small Animal Surgery at the Department of Veterinary Clinical
Sciences.
Dr. Smeak’s credentials and training include a BS and DVM with
high honor from Michigan State University, a rotating Small Animal
Internship at the Colorado State University Department of
Veterinary Clinical Sciences, and a Residency in Small Animal
Surgery at The Ohio State University, Department of Veterinary
Clinical Sciences. Dr. Smeak became a Diplomate of the American
College of Veterinary Surgeons in 1986. He has been active ever
since, serving as a productive academic surgeon, resident mentor,
researcher and clinical teacher. In addition, he is an
award-winning continuing education speaker and laboratory
instructor worldwide.
“The opportunity to work with Inotiv’s Fort Collins surgical
team is exciting to me,” said Dr. Smeak. “Inotiv has earned a
remarkable reputation for delivering excellent client experiences
with highly ethical practices. Contributing to the development of
cutting edge medical advances for humans and animals, and
supporting the growth of this dynamic Company were especially
influential in my decision to join Inotiv. I’m happy to be a part
of this team and look forward to engaging with clients.”
About the Company
The Company is a pharmaceutical development
company providing contract research services and monitoring
instruments to emerging pharmaceutical companies and the world's
leading drug development companies and medical research
organizations. The Company focuses on developing innovative
services supporting its clients’ discovery and development
objectives for improved decision-making and accelerated goal
attainment. The Company’s products focus on increasing efficiency,
improving data, and reducing the cost of taking new drugs to
market. Visit inotivco.com for more information about the
Company.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of the COVID-19 pandemic
on the economy, demand for our services and products and our
operations, including the measures taken by governmental
authorities to address the pandemic, which may precipitate or
exacerbate other risks and/or uncertainties and various other
market and operating risks, including those detailed in the
Company's filings with the U.S. Securities and Exchange
Commission.
FOR MORE INFORMATION: |
Company
Contact:Beth A. TaylorChief Financial OfficerPhone:
765.497.8381btaylor@inotivco.com |
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c05f1486-5885-4c17-9630-4148938a98b1
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024